The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysis
Sunil V. Badve(UNSW Sydney), David W. Johnson(Hennepin County), Alan Cass(University of Sydney), Vlado Perkovic(New South Wales Department of Health), Jonathan C. Craig(Flinders University), Armando Teixeira‐Pinto(The University of Sydney), Neil Boudville(The University of Western Australia), Giovanni FM Strippoli(The University of Sydney), Matthew A. Roberts(Eastern Health), Carmel M. Hawley(The University of Queensland), Gillian Whalley(University of Auckland), Swapnil Hiremath(Apple (Israel)), Elaine M. Pascoe(The University of Queensland), Suetonia C. Palmer(University of Otago)
Cited by 62
Related Papers
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Worldwide access to treatment for end-stage kidney disease: a systematic review
|The Lancet|2015|2.3k
Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies
|European Heart Journal|2012|1.3k